Systematic Comparison of Epidemic and Non-Epidemic Carbapenem Resistant Klebsiella pneumoniae Strains.

Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE

Original Publication: Lausanne : Frontiers Media SA

Carbapenem-Resistant Enterobacteriaceae*/genetics ; Epidemics* ; Klebsiella Infections*/epidemiology; Anti-Bacterial Agents/pharmacology ; Bacterial Proteins ; Carbapenems/pharmacology ; Humans ; Klebsiella pneumoniae/genetics ; Microbial Sensitivity Tests ; beta-Lactamases

Over the past few decades, extensively drug resistant (XDR) resistant Klebsiella pneumoniae has become a notable burden to healthcare all over the world. Especially carbapenemase-producing strains are problematic due to their capability to withstand even last resort antibiotics. Some sequence types (STs) of K. pneumoniae are significantly more prevalent in hospital settings in comparison to other equally resistant strains. This provokes the question whether or not there are phenotypic characteristics that may render certain K. pneumoniae more suitable for epidemic dispersal between patients, hospitals, and different environments. In this study, we selected seven epidemic and non-epidemic carbapenem resistant K. pneumoniae isolates for extensive systematic characterization for phenotypic and genotypic qualities in order to identify potential factors that precede or emerge from epidemic successfulness. Studied characteristics include growth rates and densities in different conditions (media, temperature, pH, resource levels), tolerance to alcohol and drought, inhibition between strains, ability to compensate pH, as well as various genomic features. Overall, there are clear differences between isolates, yet, only drought tolerance was found to notably associate with non-epidemic K. pneumoniae strains. We further report a preliminary study on the potential to control K. pneumoniae ST11 with an antimicrobial component produced by a non-epidemic K. pneumoniae . This component initially restricts bacterial growth, but stable resistance develops rapidly in vitro .
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Koskinen, Penttinen, Örmälä-Odegrip, Giske, Ketola and Jalasvuori.)

Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. (PMID: 19506063)
Antimicrob Agents Chemother. 2015 Oct;59(10):5873-84. (PMID: 26169401)
PLoS One. 2017 Nov 15;12(11):e0187832. (PMID: 29141051)
Crit Care Res Pract. 2012;2012:945805. (PMID: 22312484)
Sci Rep. 2018 Jun 21;8(1):9431. (PMID: 29930327)
Sci Transl Med. 2018 Aug 1;10(452):. (PMID: 30068573)
Clin Microbiol Infect. 2011 May;17(5):668-74. (PMID: 20649801)
Infect Control. 1985 Feb;6(2):68-74. (PMID: 3882593)
J Bacteriol. 1989 Dec;171(12):6430-6. (PMID: 2687234)
J Med Microbiol. 2018 Jan;67(1):118-128. (PMID: 29205138)
Antibiotics (Basel). 2019 Nov 19;8(4):. (PMID: 31752382)
Clin Microbiol Infect. 2014 Jan;20(1):34-7. (PMID: 23464880)
J Mol Med (Berl). 2019 Aug;97(8):1195-1211. (PMID: 31222488)
Am J Infect Control. 2012 Jun;40(5):421-5. (PMID: 21906844)
Microb Genom. 2018 Aug;4(8):. (PMID: 30058999)
BMC Evol Biol. 2015 Aug 19;15:165. (PMID: 26282271)
Br Med J. 1977 Nov 19;2(6098):1315-7. (PMID: 589166)
Infect Drug Resist. 2019 Dec 20;12:3935-3942. (PMID: 31908504)
J Antimicrob Chemother. 2009 Apr;63(4):654-8. (PMID: 19218573)
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):981-9. (PMID: 21918907)
Microbiol Mol Biol Rev. 2006 Sep;70(3):830-56. (PMID: 16959970)
J Bacteriol. 1982 May;150(2):490-7. (PMID: 6461633)
Cell Microbiol. 2015 Nov;17(11):1537-60. (PMID: 26045209)
BMJ Open. 2016 Mar 17;6(3):e009971. (PMID: 26988349)
Clin Infect Dis. 2017 Jul 15;65(2):208-215. (PMID: 28369261)
J Biomed Mater Res B Appl Biomater. 2018 Aug;106(6):2337-2344. (PMID: 29106034)
Clin Microbiol Rev. 1998 Oct;11(4):589-603. (PMID: 9767057)
Rev Bras Ter Intensiva. 2017 Jan-Mar;29(1):55-62. (PMID: 28444073)
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19334-9. (PMID: 19892742)
J Antimicrob Chemother. 2016 Dec;71(12):3386-3391. (PMID: 27585968)
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3574-81. (PMID: 26100894)
BMC Infect Dis. 2006 Aug 16;6:130. (PMID: 16914034)
Clin Microbiol Infect. 2011 Dec;17(12):1811-6. (PMID: 21595797)
Antimicrob Agents Chemother. 2012 May;56(5):2735-8. (PMID: 22354295)
Lancet Infect Dis. 2018 Jan;18(1):37-46. (PMID: 28864030)
Virulence. 2017 Oct 3;8(7):1111-1123. (PMID: 28402698)
Antimicrob Agents Chemother. 2010 Oct;54(10):4201-7. (PMID: 20660684)
PLoS One. 2015 Jul 21;10(7):e0133727. (PMID: 26196384)
Am J Infect Control. 2016 May 1;44(5):539-43. (PMID: 26899297)
Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54. (PMID: 19770275)
Virulence. 2013 Feb 15;4(2):107-18. (PMID: 23302790)

Keywords: XDR Klebsiella pneumoniae; antibiotic resistance; epidemic; extended-spectrum beta-lactamase; virulence

0 (Anti-Bacterial Agents)
0 (Bacterial Proteins)
0 (Carbapenems)
EC 3.5.2.6 (beta-Lactamases)

Date Created: 20210312 Date Completed: 20210616 Latest Revision: 20210616

20240104

PMC7940544

10.3389/fcimb.2021.599924

33708644